Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2
- 4 March 2005
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 328 (1) , 91-97
- https://doi.org/10.1016/j.bbrc.2004.12.145
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- U0126 and PD98059, Specific Inhibitors of MEK, Accelerate Differentiation of RAW264.7 Cells into Osteoclast-like CellsJournal of Biological Chemistry, 2002
- The phosphatidylinositol 3-Kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiationBone, 2002
- Minireview: The OPG/RANKL/RANK SystemEndocrinology, 2001
- Intracellular Calcium and Protein Kinase C Mediate Expression of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in OsteoblastsEndocrinology, 2000
- Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)Journal of Biological Chemistry, 2000
- Bisphosphonates: from the laboratory to the clinic and back againBone, 1999
- Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand FamiliesEndocrine Reviews, 1999
- A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, Regulates Osteoclast Differentiation and FunctionBiochemical and Biophysical Research Communications, 1999
- Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitroProceedings of the National Academy of Sciences, 1999
- Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal CellsJournal of Biological Chemistry, 1998